Welcome to NGC. Skip directly to: Search Box, Navigation, Content.


Brief Summary

GUIDELINE TITLE

The role of taxanes in neoadjuvant chemotherapy for women with non-metastatic breast cancer.

BIBLIOGRAPHIC SOURCE(S)

  • Breast Cancer Disease Site Group. Trudeau M, Sinclair S, Clemons M, Shelley W. The role of taxanes in neoadjuvant chemotherapy for women with non-metastatic breast cancer [full report]. Toronto (ON): Cancer Care Ontario (CCO); 2004 Dec 10. 32 p. (Practice guideline report; no. 1-20). [53 references]

GUIDELINE STATUS

BRIEF SUMMARY CONTENT

 RECOMMENDATIONS
 EVIDENCE SUPPORTING THE RECOMMENDATIONS
 IDENTIFYING INFORMATION AND AVAILABILITY
 DISCLAIMER

 Go to the Complete Summary

RECOMMENDATIONS

MAJOR RECOMMENDATIONS

  • When neoadjuvant 5-fluorouracil, doxorubicin, and cyclophosphamide (FAC) or doxorubicin and cyclophosphamide (AC) chemotherapy regimen is planned for a woman with non-metastatic breast cancer, a neoadjuvant taxane (paclitaxel or docetaxel) should also be offered. Based on evidence from clinical trials, the following regimens are recommended:
    • Paclitaxel (80 mg/m2), administered weekly for 12 weeks prior to the anthracycline-based regimen
    • Docetaxel (100 mg/m2), administered every three weeks for four cycles following the anthracycline-based regimen
  • There is no evidence at this time to suggest that one taxane is superior to the other in the neoadjuvant setting.

CLINICAL ALGORITHM(S)

None provided

EVIDENCE SUPPORTING THE RECOMMENDATIONS

TYPE OF EVIDENCE SUPPORTING THE RECOMMENDATIONS

The recommendations are supported by randomized controlled trials.

IDENTIFYING INFORMATION AND AVAILABILITY

BIBLIOGRAPHIC SOURCE(S)

  • Breast Cancer Disease Site Group. Trudeau M, Sinclair S, Clemons M, Shelley W. The role of taxanes in neoadjuvant chemotherapy for women with non-metastatic breast cancer [full report]. Toronto (ON): Cancer Care Ontario (CCO); 2004 Dec 10. 32 p. (Practice guideline report; no. 1-20). [53 references]

ADAPTATION

Not applicable: The guideline was not adapted from another source.

DATE RELEASED

2004 Dec 10

GUIDELINE DEVELOPER(S)

Program in Evidence-based Care - State/Local Government Agency [Non-U.S.]

GUIDELINE DEVELOPER COMMENT

The Practice Guidelines Initiative (PGI) is the main project of the Program in Evidence-based Care (PEBC), a Province of Ontario initiative sponsored by Cancer Care Ontario and the Ontario Ministry of Health and Long-Term Care.

SOURCE(S) OF FUNDING

Cancer Care Ontario
Ontario Ministry of Health and Long-Term Care

GUIDELINE COMMITTEE

Provincial Breast Cancer Disease Site Group

COMPOSITION OF GROUP THAT AUTHORED THE GUIDELINE

FINANCIAL DISCLOSURES/CONFLICTS OF INTEREST

Members of the Breast Cancer Disease Site Group (DSG) disclosed potential conflict of interest information.

GUIDELINE STATUS

GUIDELINE AVAILABILITY

AVAILABILITY OF COMPANION DOCUMENTS

The following are available:

PATIENT RESOURCES

None available

NGC STATUS

This summary was completed by ECRI on January 18, 2005. The information was verified by the guideline developer on February 10, 2005.

COPYRIGHT STATEMENT

DISCLAIMER

NGC DISCLAIMER

The National Guideline Clearinghouse™ (NGC) does not develop, produce, approve, or endorse the guidelines represented on this site.

All guidelines summarized by NGC and hosted on our site are produced under the auspices of medical specialty societies, relevant professional associations, public or private organizations, other government agencies, health care organizations or plans, and similar entities.

Guidelines represented on the NGC Web site are submitted by guideline developers, and are screened solely to determine that they meet the NGC Inclusion Criteria which may be found at http://www.guideline.gov/about/inclusion.aspx .

NGC, AHRQ, and its contractor ECRI Institute make no warranties concerning the content or clinical efficacy or effectiveness of the clinical practice guidelines and related materials represented on this site. Moreover, the views and opinions of developers or authors of guidelines represented on this site do not necessarily state or reflect those of NGC, AHRQ, or its contractor ECRI Institute, and inclusion or hosting of guidelines in NGC may not be used for advertising or commercial endorsement purposes.

Readers with questions regarding guideline content are directed to contact the guideline developer.


 

 

   
DHHS Logo